• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Christopher Nixon Cox Named Chairman of High-Trend International Group

    3/13/25 9:00:00 AM ET
    $ANRO
    $HTCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Marine Transportation
    Consumer Discretionary
    Get the next $ANRO alert in real time by email

    SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid rapid expansion.

    Mr. Christopher Nixon Cox has served as a member of the board of directors of Alto Neuroscience, Inc. (ANRO on NYSE) since April 2022. Since December 2021, Mr. Cox has served as Chief Executive Officer of Lightswitch Capital, a private equity firm dedicated to funding breakthrough therapies for severe diseases and advancing green infrastructure in emerging markets. In addition, Mr. Cox has served as Chief Executive Officer of Argali Carbon Corporation, a carbon offset developer, since November 2022 and of BioSource Feed Corporation, a pioneer in sustainable agriculture, since October 2023. From December 2018 until March 2020, Mr. Cox served as Vice Chairman of Brightsphere, Inc., a publicly traded asset manager. Mr. Cox has also served as the Managing Partner and co-founder of OC Global Partners LLC, a financial services company, since October 2006.

    Previously, Mr. Cox served as a corporate associate at the law firm of Weil, Gotshal & Manges LLP from 2004 to 2006. Mr. Cox received a J.D. degree from the New York University School of Law, a certificate in Finance from New York University Stern School and a B.A. degree in Politics from Princeton University.

    As the grandson of President Richard Nixon, Mr. Cox upholds his family's legacy of public service and international diplomacy. He serves on the Board of the Richard Nixon Foundation and founded the Sunswyck Foundation to strengthen U.S.-China relations.

    Mr. Cui joins HTCO with over two decades of experience in cross-border finance, mergers and acquisitions, and large-scale infrastructure investments. During his tenure as Director of Investments at HNA Group, a global aviation, travel, and financial services conglomerate, he led a team of 10 across Hong Kong and New York to execute over $10 billion in strategic deals. A licensed attorney in New York and USPTO-registered patent practitioner, Mr. Cui holds a Juris Doctor degree from Georgetown University Law Center and a B.S. degree in Mathematics and Computer Science from the University of Illinois.

    Shixuan He, CEO of the company commented that,"Mr. Cox's appointment marks a milestone in the Company's development, and his expertise will be instrumental in advancing our maritime low-carbon initiatives. His deep understanding of capital markets and experience in frontier green technologies align with our vision to become a leader in ocean-based decarbonization. Equally critical is his ability to strengthen our traditional shipping operations in the U.S."

    Mr. He added: "We are equally thrilled to welcome Bo Cui as our Chief Legal Officer. His proven track record in managing complex cross-border investments, regulatory compliance, and technology-driven ventures will be invaluable as we navigate global markets and accelerate our green transition. Bo's dual expertise in law and emerging technologies positions him uniquely to lead our legal strategy and risk management efforts."

    About High-Trend International Group

    High-Trend is an international shipping company.

    Forward Looking Statements

    This announcement contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words "believe," "expect," "anticipate," "future," "will," "intend," "plan," "estimate" or similar expressions, are "forward-looking statements". Such statements include, but are not limited to risks detailed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the fiscal year ended October 31, 2024. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. All information provided in this press release is as of the date of the publication, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Cision View original content:https://www.prnewswire.com/news-releases/christopher-nixon-cox-named-chairman-of-high-trend-international-group-302400953.html

    SOURCE High-Trend International Group

    Get the next $ANRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANRO
    $HTCO

    CompanyDatePrice TargetRatingAnalyst
    Alto Neuroscience Inc.
    $ANRO
    10/23/2024$29.00 → $4.00Outperform → Neutral
    Wedbush
    Alto Neuroscience Inc.
    $ANRO
    10/23/2024Buy → Neutral
    Rodman & Renshaw
    Alto Neuroscience Inc.
    $ANRO
    9/3/2024$29.00Outperform
    Wedbush
    Alto Neuroscience Inc.
    $ANRO
    2/27/2024Outperform
    William Blair
    Alto Neuroscience Inc.
    $ANRO
    2/27/2024Outperform
    TD Cowen
    Alto Neuroscience Inc.
    $ANRO
    2/27/2024$32.00Outperform
    Robert W. Baird
    Alto Neuroscience Inc.
    $ANRO
    2/27/2024$33.00Buy
    Jefferies
    Alto Neuroscience Inc.
    $ANRO
    2/27/2024$32.00Buy
    Stifel
    More analyst ratings

    $ANRO
    $HTCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • High-Trend International Group Held Extraordinary General Meeting for Share Capital Restructure

      SINGAPORE, July 18, 2025 /PRNewswire/ -- High-Trend International Group (the "Registrant" or the "Company") (NASDAQ:HTCO), a global ocean technology company, today announced a correction to its press release issued on July 17, 2025, in order to provide clarification about the time of effectiveness of the proposed share consolidation. Please see below the corrected original press release. High-Trend International Group (the "Registrant" or the "Company") (NASDAQ:HTCO), a global ocean technology company, held its Extraordinary General Meeting of Shareholders (the "Meeting") on July 16, 2025. At the Meeting, the shareholders voted to approve (1) the proposal that every 25 issued and unissued c

      7/18/25 11:00:00 PM ET
      $HTCO
      Marine Transportation
      Consumer Discretionary
    • High-Trend International Group Held Extraordinary General Meeting for Share Capital Restructure

      SINGAPORE, July 17, 2025 /PRNewswire/ -- High-Trend International Group (the "Registrant" or the "Company") (NASDAQ: HTCO), a global ocean technology company, held its Extraordinary General Meeting of Shareholders (the "Meeting") on July 16, 2025. At the Meeting, the shareholders voted to approve (1) the proposal that effective immediately following the close of the Meeting, every 25 issued and unissued class A ordinary shares of a par value of US$0.0001 each and every 25 issued and unissued class B ordinary shares of a par value of US$0.0001 each in the Company's existing share capital be consolidated into 1 class A ordinary share of a par value of US$0.0025 and 1 class B ordinary share of

      7/17/25 9:00:00 AM ET
      $HTCO
      Marine Transportation
      Consumer Discretionary
    • Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

      –  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

      6/30/25 8:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    $HTCO
    SEC Filings

    See more
    • Amendment: SEC Form 6-K/A filed by High-Trend International Group

      6-K/A - High-Trend International Group (0001928948) (Filer)

      7/18/25 5:00:04 PM ET
      $HTCO
      Marine Transportation
      Consumer Discretionary
    • SEC Form 6-K filed by High-Trend International Group

      6-K - High-Trend International Group (0001928948) (Filer)

      7/17/25 9:00:02 AM ET
      $HTCO
      Marine Transportation
      Consumer Discretionary
    • Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.

      SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

      7/16/25 7:02:16 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    $HTCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alto Neuroscience downgraded by Wedbush with a new price target

      Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

      10/23/24 7:37:30 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience downgraded by Rodman & Renshaw

      Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

      10/23/24 6:52:50 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Alto Neuroscience with a new price target

      Wedbush initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $29.00

      9/3/24 7:41:31 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    $HTCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF OPERATING OFFICER Hanley Jr. Michael Conick

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/8/25 5:22:49 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF MEDICAL OFFICER Savitz Adam

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/8/25 5:22:02 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT AND CEO Etkin Amit

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/8/25 5:21:22 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    $HTCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Savitz Adam bought $190,833 worth of shares (15,000 units at $12.72) (SEC Form 4)

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/11/24 4:15:04 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Nicholas Conrad bought $100,628 worth of shares (6,150 units at $16.36), increasing direct ownership by 30% to 26,866 units (SEC Form 4)

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      4/1/24 4:15:30 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    $HTCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alto Neuroscience Inc.

      SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/14/24 5:46:11 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alto Neuroscience Inc.

      SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/14/24 7:00:29 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alto Neuroscience Inc.

      SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/12/24 9:50:14 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    $HTCO
    Leadership Updates

    Live Leadership Updates

    See more
    • High-Trend International Group Appoints Brian B. Su as Independent Director and Chairman of the Compensation Committee

      NEW YORK, June 9, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) ("the Company"), a publicly traded international shipping and logistics company, today announced the appointment of Mr. Brian B. Su as an Independent Director and Chairman of the Company's Compensation Committee, effective immediately. Mr. Su is a distinguished international business advisor and compliance expert with over 30 years of experience in cross-border investment, regulatory strategy, and market expansion. He is the Founder and President of Artisan Business Group, Inc., a U.S.-based consultancy headquartered in Springfield, Illinois. The firm has built a strong track record advising U.S. and global

      6/9/25 9:30:00 PM ET
      $HTCO
      Marine Transportation
      Consumer Discretionary
    • Christopher Nixon Cox Named Chairman of High-Trend International Group

      SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

      3/13/25 9:00:00 AM ET
      $ANRO
      $HTCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Marine Transportation
      Consumer Discretionary
    • Caravelle International Group Announces New CEO and Audit Committee Chair to Trailblaze Shipping Decarbonization and Carbon Asset Management Platform

      SINGAPORE, Jan. 14, 2025 /PRNewswire/ -- Caravelle International Group (NASDAQ:HTCO), a global ocean technology company, today announced appointment of Shixuan He as the Company's Chief Executive Officer and Xuanhua Xi as an independent director and Chairman of the Audit Committee. These strategic appointments are aimed at driving the company's transition towards sustainable maritime practices and enhancing its management systems. Mr. He, with his 15 years of management experience, has accumulated rich industry insights and exceptional leadership skills. His career has spanned

      1/14/25 9:07:00 AM ET
      $HTCO
      Marine Transportation
      Consumer Discretionary

    $ANRO
    $HTCO
    Financials

    Live finance-specific insights

    See more
    • Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

      –  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

      6/30/25 8:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

      – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

      6/3/25 6:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care